Study Summary
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer that has failed at least first-line therapy.
Interested in this trial?
Submit an InquiryInterventions
IM92 CAR-T cellsDRUG
2.5×10\^8 CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chinese PLA GENERAL HOSPITAL | Beijing | Beijing Municipality | China |